Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIBIT-M2: Fotemustine vs Ipilimumab/Nivolumab in Melanoma Brain Metastases
NCT02460068Phase 3Unknown
- Sponsor
- NIBIT Foundation
- Start
- Dec 2012
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ipilimumab, nivolumab in melanoma, brain metastases, sponsored by NIBIT Foundation. Status: unknown.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NCT02460068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460068.